Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY: GSK )

39.23 +0.35 (+0.90%)
Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
37 38 Next >
Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood'
Moderna unveiled promising results in flu on Wednesday, adding to its respiratory suite. 
Via Investor's Business Daily
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for... 
Via Benzinga
Exposures Product Safety
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Viatris, GSK, and Organon are all trading at less than 7 times earnings. 
Via The Motley Fool
GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
From GSK plc
Via Business Wire
Peering Into GSK's Recent Short Interest
Via Benzinga
Looking Into GSK's Recent Short Interest
Via Benzinga
Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development'
Presidential hopeful Vivek Ramaswamy and Warren Buffett may share different political ideologies but they have at least a couple of things in common. 
Via Benzinga
7 Stocks Hedge Funds Are Loading Up On
Hedge funds and many other financial institutions are loading up on these names considered to be among top institutional stock picks. 
Via InvestorPlace
GSK To Invest $272M In New Vaccine Facility Near Brussels, Slated To Open In 2027
GSK Plc (NYSE: GSK) has made an investment of over €250 million ($272 million) in a vaccine facility located in Belgium. 
Via Benzinga
3 Growth Stocks to Ride the Coming Bull Market in Style
Bull markets always follow bear markets, and these three companies are growth stocks to buy for the next wave higher 
Via InvestorPlace
3 Sorry Pharma Stocks to Sell in August Before It’s Too Late
Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell. 
Via InvestorPlace
A Look Into GSK Inc's Price Over Earnings
Via Benzinga
Is GSK Stock Worth Buying Right Now?
GSK stock could be a bargain. 
Via The Motley Fool
A Look Into GSK's Debt
Via Benzinga
FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth
Monday, the FDA approved Pfizer Inc's (NYSE: PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth... 
Via Benzinga
Exposures Product Safety
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
From GSK plc
Via Business Wire
Is GSK an Excellent Dividend Stock to Buy for Passive Income Investors?
GSK offers a robust dividend yield, but that's not the only thing to consider. 
Via The Motley Fool
3 Pharma Stocks to Sell in August Before They Crash and Burn
Stay far away from these pharma stocks that are suffering from declining sales and weak pipelines of future products. 
Via InvestorPlace
GSK, Pfizer Lock Horns Over Patent Fight Related To Respiratory Syncytial Virus Vaccine
GSK Plc (NYSE: GSK) has sued Pfizer Inc (NYSE: PFE) in Delaware court, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's four patent rights in its RSV  
Via Benzinga
GSK's Jemperli Plus Chemo Combo Scores FDA Approval As First New Frontline Treatment For Certain Type Of Endometrial Cancer
The FDA approved GSK plc's (NYSE: GSK) Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for primary advanced or recurrent endometrial cancer... 
Via Benzinga
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
From GSK plc
Via Business Wire
If You Can Only Buy One Dividend Stock, It Better Be One of These 7 Names
Here are seven of the best dividend stocks to consider immediately. Better, each of these stocks have strong, stable businesses. 
Via InvestorPlace
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits. 
Via InvestorPlace
GSK Says 'Excellent' Q2 Performance Boosted By Vaccine & HIV Drug Sales, Raises 2023 Outlook
GSK plc (NYSE: GSK) reported Q2 FY23 sales of £7.18 billion ($8.97 billion), up 4% Y/Y on t 
Via Benzinga
Pharma Giant GSK Beats Second-Quarter Goals On Growth In Vaccines, General Medicines
Pharmaceutical giant GSK beat expectations for the second quarter and raised its forecast for the full year. GSK stock rose on the news. 
Via Investor's Business Daily
Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories
Wall Street Journal 
Via Benzinga
GSK-Pfizer Backed HIV-Focused Unit ViiV Healthcare's Cabotegravir Injected Drug, Tablets Secure European Backing For Approval
ViiV Healthcare received a positive opinion from the European Medicines Agen 
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market. 
Via InvestorPlace
Why Shares of Vir Biotechnology Are Plunging Thursday
The company had disappointing trial news for one of its lead therapies. 
Via The Motley Fool
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of  
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.